Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Sagent Pharmaceuticals, Inc. | d900426dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 25, 2015
Sagent Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Commission File Number: 1-35144
| Delaware | 98-0536317 | |
| (State or other jurisdiction of incorporation) |
(IRS Employer Identification No.) |
1901 N. Roselle Road, Suite 700, Schaumburg, Illinois 60195
(Address of principal executive offices, including zip code)
(847) 908-1600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
(b) On March 25, 2015, Jeffrey Yordon retired as Chairman and Chief Executive Officer of Sagent Pharmaceuticals, Inc. (the “Company”), effective as of such date. Mr. Yordon remains a member of the Board of Directors of the Company (the “Board”), but is no longer an employee of the Company.
On March 25, 2015, James Hussey advised the Board of his decision to leave the Company, and the Board accepted his resignation as President of the Company, effective as of such date.
(e) The Company agreed to treat the termination of Mr. Yordon’s employment with the Company as a “Qualifying Termination” under his Employment Agreement, dated January 20, 2011. Accordingly, he will be entitled to receive the severance and other benefits specified in Section 9(b) of his Employment Agreement.
Item 8.01 Other Events
On March 26, 2015, the Company issued a press release announcing the executive management changes described in Item 5.02 above. A copy of that press release is furnished herewith as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) The following exhibit is being furnished with this Current Report on Form 8-K.
| Exhibit |
Description | |
| 99.1 | Sagent Pharmaceuticals, Inc. Press Release, dated March 26, 2015. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| SAGENT PHARMACEUTICALS, INC. | ||||||
| Date: March 26, 2015 | ||||||
| /s/ Michael Logerfo | ||||||
| Name: | Michael Logerfo | |||||
| Title: | Executive Vice President, Chief Legal Officer and Corporate Secretary | |||||